Fennec Pharmaceuticals INC Form 4 insider transactions

Fennec Pharmaceuticals Director Rosty Raykov reported the future sale of 10,000 common shares at $8.09 each, executed under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock, increasing his beneficial ownership to 65,878 shares.

Fennec Pharmaceuticals Inc.'s Chief Financial Officer, Robert Andrade, acquired 2,431 common shares through the vesting of previously awarded restricted stock.

Fennec Pharmaceuticals Director Chris A. Rallis reported the exercise of 2,127 options at $2.35 per share and the subsequent sale of 1,119 shares at $8.71 to cover tax liabilities, as part of a pre-arranged 10b5-1 plan.

Rosty Raykov, a Director at Fennec Pharmaceuticals Inc., sold 10,000 common shares for $8.61 each, as part of a pre-scheduled 10b5-1 trading plan.

Fennec Pharmaceuticals Inc. Director Rosty Raykov acquired 5,208 common shares through the vesting of previously awarded restricted stock, increasing his total beneficial ownership to 70,670 shares.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, has acquired 2,431 common shares through the vesting of previously awarded restricted stock, increasing his total beneficial ownership to 163,382 shares.

Rosty Raykov, a Director at Fennec Pharmaceuticals Inc. (FENC), sold 10,000 common shares for $7.78 per share on June 5, 2025, as part of a pre-existing 10b5-1 trading plan.

Fennec Pharmaceuticals Inc. director Jodi Cook was granted 20,000 non-qualified stock options, exercisable at $7.88 per share, pursuant to the company's Equity Incentive Plan.

Fennec Pharmaceuticals Inc. Director Marco Maria Brughera was granted 20,000 non-qualified stock options at an exercise price of $7.88, fully vested on the grant date of June 3, 2025.

Fennec Pharmaceuticals Inc. Director Chris Rallis was granted 20,000 non-qualified stock options, fully vested on the grant date, with an exercise price of $7.88 per share.

Fennec Pharmaceuticals Inc. Director Khalid Islam was granted 25,000 non-qualified stock options at an exercise price of $7.88, fully vested on the grant date of June 3, 2025.

Fennec Pharmaceuticals Inc. Director Rosty Raykov has increased his beneficial ownership of common shares by 5,208 units following the release of restricted stock.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, increased his direct beneficial ownership by 2,431 common shares through the release of restricted stock.

Fennec Pharmaceuticals Inc.'s Chief Financial Officer, Robert Andrade, has exercised stock options to acquire 8,220 common shares, increasing his direct beneficial ownership.

Fennec Pharmaceuticals CEO Jeffrey S. Hackman reports purchasing additional company shares on May 16 and May 19, 2025.

Director Rosty Raykov of Fennec Pharmaceuticals reports acquiring shares through vesting and selling shares to cover tax obligations.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition and disposal of common shares related to the release of restricted stock.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares at $6.31 per share on May 5, 2025, according to a Form 4 filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares previously restricted, increasing his total holdings to 133,633 shares.

Director Rosty Raykov reports the release of restricted shares of Fennec Pharmaceuticals.

Director Chris Rallis of Fennec Pharmaceuticals reports exercising options and selling shares to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares on April 4, 2025, at a price of $5.25 per share, according to a Form 4 filing.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4/A filing.

Pierre Sayad, Chief Medical Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4 filing.

Terry Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reports the acquisition of 10,000 restricted share units.

CEO Jeffrey Hackman receives 75,000 restricted share units and options for 50,000 shares of Fennec Pharmaceuticals stock.

Robert Andrade, CFO of Fennec Pharmaceuticals, was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.

CEO Jeffrey Hackman of Fennec Pharmaceuticals was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.

Terry Evans, Chief Commercial Officer of Fennec Pharmaceuticals, received 10,000 restricted share units under the company's 2020 Equity Incentive Plan.